Obstetrx

What Obstetrx does

Obstetrx is a privately-held, pre-revenue medical device company developing a single core product: the XSTAT PPH uterine tamponade device for the treatment of postpartum hemorrhage (PPH). The company is headquartered in Wilsonville, Oregon, was incorporated as a separate entity in 2019, and operates with 1–10 employees. Its mission is to eliminate maternal death and disability from PPH, a condition affecting approximately 14 million women annually and causing an estimated 130,000 deaths worldwide (~20% of all maternal deaths).

The device is a novel adaptation of the XSTAT self-expanding wound dressing, originally developed by RevMedx Inc for battlefield hemorrhage control and licensed to Obstetrx for obstetric use. Compressed medical-grade minisponges are delivered into the postpartum uterus via a curved obstetrical applicator through a routine vaginal exam, expanding inside a porous pouch to generate uniform hemostatic pressure. A 2019 nine-woman pilot study in Zambia demonstrated 100% hemostasis with a 60-second average application time, 20-second average removal, and no device-related adverse events; results were published in Obstetrics & Gynecology in November 2020. Preclinical proof-of-concept data was previously published in BMC Pregnancy and Childbirth (2017).

Obstetrx's business model is planned direct hospital sales of the hardware device to obstetric units and maternity wards in the US and globally, with anticipated future use of medical device distributors. The device is currently limited by U.S. law to investigational use, and the company is pursuing regulatory clearance ahead of commercialization. Core technology and clinical partners include RevMedx Inc (technology licensor), Oregon Health & Science University (research co-developer under a Saving Lives at Birth Grand Challenge grant), and Global Good (Bill Gates / Nathan Myhrvold partnership) as a supporter. Capital to date consists of a $3 million exempt securities offering with $1.1 million sold as of August 2021 (SEC Form D).

Name

Obstetrx

Legal name

Obstetrx, Inc.

Website

https://obstetrx.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Obstetrx is a pre-revenue medical device company developing the XSTAT PPH uterine tamponade device, which adapts battlefield hemorrhage-control technology to rapidly stop postpartum bleeding in obstetric patients. It targets hospitals and maternal health systems in the US and globally, pursuing regulatory clearance ahead of commercialization.

Ownership category

akta.pro rank

Product category

Obstetric Medical Devices

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

akta.pro secondary industry

Labor & Delivery / Obstetric Hospitalist (OB Hospitalist) Services (HLAKAJAK)

Keywords

• Postpartum hemorrhage treatment
• Uterine tamponade device
• Maternal health devices
• Obstetric medical devices
• Hemorrhage control technology

Headquarters

HQ city

Wilsonville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: The company is developing and preparing to commercialize its novel uterine tamponade device for postpartum hemorrhage. Revenue will be generated through direct sales of the device to hospitals and healthcare providers. Currently in pre-commercial stage with investigational device status.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Obstetrx is developing the XSTAT PPH, a novel investigational medical device that delivers compressed medical-grade minisponges into the postpartum uterus via a curved obstetrical applicator. The rapidly-expanding sponges fill the uterine cavity and generate uniform hemostatic pressure to stop severe postpartum bleeding within approximately 60 seconds, with non-surgical removal via an attached retrieval strand.

Product overview

Obstetrx is developing a single core product: the XSTAT PPH uterine tamponade device. This novel medical device adapts battlefield hemorrhage-control technology (originally developed by RevMedx for the US military) for obstetric applications. The device consists of compressed minisponges deployed via a syringe-like curved applicator through a porous, expandable pouch, enabling rapid insertion during vaginal exam and immediate hemostatic effect. The company is currently working toward regulatory clearance and commercialization in the US and globally.

Differentiator

Problem solved

Functional benefit

Products and services

• XSTAT PPH Uterine Tamponade Device A novel investigational medical device for treating postpartum hemorrhage that delivers compressed medical-grade minisponges into the postpartum uterus through a curved obstetrical applicator during a routine vaginal exam. Sponges rapidly expand inside the uterus to generate uniform hemostatic pressure and stop severe bleeding within approximately 60 seconds. Designed for use by obstetricians, midwives, and other maternity healthcare providers in hospitals and birthing facilities.

Quantifiable outcome

• 100% hemostasis rate achieved in all nine postpartum hemorrhage cases in pilot study
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• RevMedx InccoreTechnology or Integration · 1 January 2014RevMedx Inc developed the XSTAT hemorrhage-control device for the US military to stop severe bleeding from battlefield wounds. They partnered with Obstetrx to adapt this proven combat medicine technology for obstetric applications. RevMedx licensed the XSTAT technology foundation for development of the postpartum hemorrhage device. The companies share the Wilsonville, OR address.
• Oregon Health & Science University (OHSU)coreStrategic or Co-development PartnerOHSU received a Saving Lives at Birth Grand Challenge grant to conduct early-stage research and development with RevMedx. The OHSU team collaborated on adapting the XSTAT technology for obstetric use, culminating in pre-clinical proof-of-concept studies. OHSU researchers co-authored peer-reviewed publications on the technology.
• Global GoodminorStrategic or Co-development PartnerPartner and supporter listed on the Obstetrx partners page. Global Good is a collaboration between Bill Gates and Nathan Myhrvold focused on inventing technology to improve lives in developing countries.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Cook Medical: Manufacturer of the Bakri Postpartum Balloon, the leading mechanical tamponade device used to treat postpartum hemorrhage. Cook Medical is the dominant incumbent in PPH uterine tamponade and competes head-to-head with Obstetrx's value proposition of faster, easier deployment.
• Laborie Medical Technologies: Owns the legacy Clinical Innovations obstetric device portfolio (e.g., Kiwi vacuum-assisted delivery, Cordless HotDog warming). Sells into the same L&D hospital buyer and competes for category adoption in obstetric procedural devices.
• Teleflex: Diversified medical device company with an obstetric and surgical access portfolio used in labor & delivery and women's health procedures. Comparable in serving the same hospital OB/GYN buyer with surgical devices, though Teleflex is far broader and more established.
• Becton, Dickinson and Company (BD): Global medical device incumbent with a broad women's health, surgical, and hemorrhage management portfolio. Targets overlapping hospital customers and would represent a strategic acquirer or large-scale competitor for any successful PPH tamponade device.
• CooperSurgical: A large women's-health medical device company offering a broad portfolio of obstetric and gynecologic products including surgical instruments used in postpartum care. CooperSurgical overlaps with Obstetrx in target customer (OB/GYN hospital units) and adjacent surgical-device categories.
• Utah Medical Products: Public medical device company specializing in women's health and neonatal products including devices used during delivery and postpartum care. Comparable as a focused niche device maker selling into the same obstetric hospital channel.
• Hologic: Large women's health device and diagnostics company including surgical solutions used in obstetric and gynecologic procedures. Hologic competes for hospital women's-health capital budgets and would be a potential strategic acquirer of an innovative PPH device.

Emerging players

• Z-Medica (Salinger / QuikClot): Developer of hemostatic agents and devices (QuikClot Combat Gauze) originally for battlefield hemorrhage control - the same military-medicine origin as Obstetrx's underlying XSTAT platform. Comparable origin story in translating combat-proven hemorrhage technology into clinical use.

Direct peers

• RevMedx Inc: The original developer of the XSTAT self-expanding wound dressing and licensor of the core mini-sponge technology to Obstetrx. Operates from the same Wilsonville address and shares the mini-sponge hemostatic device platform, making it both a partner and direct technological peer.
• Organon (JADA System): Acquired the JADA System, a low-level uterine tamponade device for postpartum hemorrhage that gained FDA clearance in 2020. Direct competitor in the same PPH tamponade category, targeting the same hospital L&D units as Obstetrx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Obstetrx